---
title: "廣西梧州中恆集團獲得中國批准用於治療胸部和術後疼痛的藥物"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/257850525.md"
description: "（MT Newswires）-- 根據週四在上海證券交易所的文件，中國醫療產品管理局批准了廣西梧州中恆（SHA:600252）的硝苯地平片和酮咯酸託瑞米芬注射液。文件指出，硝苯地平片適用於心絞痛或胸痛，而酮咯酸託瑞米芬注射液適用於術後鎮痛。週四下午交易中，股價下跌了 1%"
datetime: "2025-09-18T07:10:34.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/257850525.md)
  - [en](https://longbridge.com/en/news/257850525.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/257850525.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/257850525.md) | [English](https://longbridge.com/en/news/257850525.md)


# 廣西梧州中恆集團獲得中國批准用於治療胸部和術後疼痛的藥物

(MT Newswires) -- China's medical product administrator approved Guangxi Wuzhou Zhongheng's (SHA:600252) nicorandil tablets and ketorolac tromethamine injection, according to a Thursday filing with the Shanghai bourse.

The nicorandil tablets are indicated for angina pectoris or chest pain, while the ketorolac tromethamine injection is indicated for post-operative pain relief, the filing said.

Shares fell 1% during afternoon trading on Thursday.

### 相關股票

- [中恆集團 (600252.CN)](https://longbridge.com/zh-HK/quote/600252.CN.md)

## 相關資訊與研究

- [龍湖集團發盈警](https://longbridge.com/zh-HK/news/278150471.md)
- [石藥集團茚達特羅莫米松吸入粉霧劑獲準內地開展臨牀試驗](https://longbridge.com/zh-HK/news/278006868.md)
- [保利置業集團︰2 月合同銷售金額按年跌 39% 至 22 億元人幣](https://longbridge.com/zh-HK/news/278063267.md)
- [彭博：黑石與新世界注資談判陷入僵局，因鄭氏家族不願放棄控制權](https://longbridge.com/zh-HK/news/277713884.md)
- [康哲藥業小核酸減肥針獲內地批准用於超重或肥胖臨牀試驗](https://longbridge.com/zh-HK/news/277851370.md)